Kalydeco Now Approved for Expanded Cystic Fibrosis Treatment

Published Online: Friday, May 19th, 2017
FDA officials have announced the expanded approval of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to triple the number of rare gene mutations of cystic fibrosis that the drug is indicated to treat, from 10 mutations to 33.
 
The FDA based its approval on results of laboratory testing in conjunction with evidence from previous human clinical trials. Researchers identified additional mutations that responded to Kalydeco in testing and were able to extrapolate that data demonstrated in earlier clinical trials.
 
Kalydeco is available as tablets or oral granules and is to be taken 2 times a day with fat-containing food. It is designed to help the protein made by the CFTR gene function better and improve lung function and other aspects of cystic fibrosis.
 
According to an FDA press release, the expanded indication will affect another 3% of the cystic fibrosis population.
 
Adverse events that have been associated with this treatment include headache, upper respiratory tract infection, stomach pain, diarrhea, rash, nausea, and dizziness.
 
Reference
 
FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis [news release]. FDA’s website. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm559212.htm. Accessed May 18, 2017. 

Current Issue

The Educated Patient

Kristen Marjama, DNP, FNP-BC
The National Health Interview Survey in 2014 estimated that 17.7 million adults and 6.3 million children had asthma.
Mary McCormack, MSN, APNC, MPH
The World Gastroenterology Organization describes the prevalence of celiac disease as a “statistical iceberg” in today’s health climate.
Melissa DeCapua, DNP, PMHNP-B-C
Diabetic retinopathy causes more losses of vision worldwide than any other eye disease, affecting 33% of the 285 million individuals suffering from diabetes.
Janet Gilbreath, DNP, MBA, MSN, FNP-BC
Head lice are 6-legged insects about the size of a sesame seed that cling to the scalp and neck and survive by feeding on human blood.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
ONCLive
OTCGuide
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Advertise
Careers
Contact Us
Feedback
Privacy
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2017
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.